Literature DB >> 22898201

Paediatric brain tumours treated at a single, tertiary paediatric neurosurgical referral centre from 1999 to 2010 in Australia.

Mahesh Ramanan1, Raymond Chaseling.   

Abstract

Paediatric brain tumours are the most common solid tumour of childhood and the most common cancer cause of death among children. A retrospective review of 313 histopathologically proven brain tumours over an 11-year period has been performed at the Children's Hospital Westmead, New South Wales, Australia, to determine proportions and locations of different tumours, age distribution, survival rates and usage of various treatment modalities. Pilocytic astrocytoma was the most common paediatric brain tumour (29%) followed by medulloblastoma (12%) and ependymoma (6%). Most tumours were histologically benign (59%), and 42% of tumours were located in the posterior fossa. The average age at diagnosis was 7.9 years. About 50% of children were treated with surgery alone, whereas the other 50% had surgery or biopsy plus adjuvant treatment. The overall one-year survival rate was 89% and the five-year survival rate was 80%. The five-year survival rates for pilocytic astrocytoma was 91%; medulloblastoma, 75%; ependymoma, 82%; and high grade glioma, 15%. Thus, a large proportion of paediatric brain tumours were histologically benign and were treated with surgery alone, but a subset of benign tumours required adjuvant treatment and were associated with mortality (25%). The overall survival rates were high and are improving, although for some tumours, such as high grade glioma, the outlook remains poor. Crown
Copyright © 2012. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22898201     DOI: 10.1016/j.jocn.2012.01.028

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  8 in total

1.  Pediatric central nervous system tumors: review of a single Portuguese institution.

Authors:  Maria M Santos; Cláudia C Faria; José Miguéns
Journal:  Childs Nerv Syst       Date:  2016-04-23       Impact factor: 1.475

Review 2.  2-deoxy-2-((18)F)fluoro-D-glucose positron emission tomography/computed tomography imaging in paediatric oncology.

Authors:  John Freebody; Eva A Wegner; Monica A Rossleigh
Journal:  World J Radiol       Date:  2014-10-28

3.  ASYMMETRIC CELL DIVISION: IMPLICATIONS FOR GLIOMA DEVELOPMENT AND TREATMENT.

Authors:  Kate Marie Lewis; Claudia Petritsch
Journal:  Transl Neurosci       Date:  2013-12       Impact factor: 1.757

4.  The Satisfactory Surgical Outcome of Posterior Fossa Brain Tumors in Children at Civil Hospital, Karachi.

Authors:  Jahanzeb Kakar; Junaid Ashraf; Atiq Ahmed Khan; Muhammad Imran; Muhammad Asim Rehmani; Shiraz Ahmed Ghori; Mohammad Faaiq Ali
Journal:  Asian J Neurosurg       Date:  2020-05-29

5.  The Ketogenic Diet Does Not Affect Growth of Hedgehog Pathway Medulloblastoma in Mice.

Authors:  Mai T Dang; Suzanne Wehrli; Chi V Dang; Tom Curran
Journal:  PLoS One       Date:  2015-07-20       Impact factor: 3.240

6.  Epidemiology of brain tumors in children aged two and under: A 10-year single-institute study.

Authors:  Jianzhong Yu; W E Shi; Rui Zhao; Xiaofeng Gao; Hao Li
Journal:  Oncol Lett       Date:  2015-02-09       Impact factor: 2.967

7.  Tumors of the Central Nervous System: An 18-Year Retrospective Review in a Tertiary Pediatric Referral Center.

Authors:  Hosein Aghayan Golkashani; Hossein Hatami; Abdonaser Farzan; Hassan Reza Mohammadi; Yalda Nilipour; Maliheh Khoddami; Farzaneh Jadali
Journal:  Iran J Child Neurol       Date:  2015

8.  Clinical profile, treatment and outcome of pediatric brain tumors in Serbia in a 10-year period: A national referral institution experience.

Authors:  Dragana Stanić; Danica Grujičić; Tatjana Pekmezović; Jelena Bokun; Marija Popović-Vuković; Dragana Janić; Lejla Paripović; Vesna Ilić; Marija Pudrlja Slović; Rosanda Ilić; Savo Raičević; Milan Sarić; Ivana Mišković; Borko Nidžović; Marina Nikitović
Journal:  PLoS One       Date:  2021-10-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.